Spanish multicentre PIBHE study: Prevalence and immunisation of chronic hepatitis B in haemodialysis patients in Spain

García-Agudo, Rebeca; Rabih, Sami Aoufi; Cuadrado, Guillermina Barril; Vega, B Proy; Arias, Ángel; Gallego, José Antonio

doi:10.1016/j.nefroe.2016.04.004

Cited by 7 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our neighbors, this rate was found to be 3.2% for Iraq and 2% for Iran (21,22). In countries from different continents, the prevalence of HBV positivity was found as 2.98% for Botswana, 16.1% for Pakistan, 0% for Brazil, 12% for Kosovo, and 1.03% for Spain (21)(22)(23)(24)(25)(26)(27). As seen, the rates vary from by country and even in different geographical regions of one country.…”

Section: Discussionsupporting

confidence: 49%

Overview of blood-borne viral infections in hemodialysis patients: hepatitis B, hepatitis C, human immunodeficiency virus infections

Aydın

Ergen

Erbakan

et al. 2022

Journal of Health Sciences and Medicine

View full text Add to dashboard Cite

Aim: This study aimed to examine the blood-borne viral infections such as hepatitis B, hepatitis C and human immunodeficiency virus (HIV) and to determine the risk factors in hemodialysis patients. Material and Method:The datas of patients who underwent hemodialysis in the hemodialysis unit of our hospital between March 1, 2020 and March 1, 2021 were reviewed retrospectively. Their sociodemographic characteristics, habits, underlying diseases and virological indicators related to hepatitis B, hepatitis C and HIV were obtained from patient files and hospital data processing system.Results:A total of 96 patients were included in the study. Of them, 43.8% (n=42) were female and 56.2% (n=54) were male. Their mean age was 62.61±18.11 years, ranging from 17 to 92. The duration of dialysis was less than 3 months for 46.9% (n=45) of the patients, between 3 months and 3 years for 19.8% (n=19), and 3 years and above for 33.3% (n=32). Thirty patients (31.3%) had diabetes mellitus. In addition, 1% (n=1) of the patients had HBsAg positivity, 3.1% (n=3) had anti-HCV positivity, 59.4% (n=57) had Anti-HBs positivity and 2.1% (n=2) had anti-HIV positivity. No statistically significant difference was found between the patients' HBsAg, anti-HCV and anti-HIV positivity according to gender, duration of dialysis, dialysis application site, alcohol use, surgical intervention and blood transfusion history (p>0.05). Conclusion:Hemodialysis patients may be at risk for hepatitis B, hepatitis C and HIV infection if infection control guidelines are not followed strictly. In addition to complying with these guidelines, both health workers and patients should be trained constantly, patients' virological indicators should be tested regularly and hepatitis B vaccine should be administered to hemodialysis patients without seroconversion.

show abstract

Section: Discussionsupporting

confidence: 49%

Overview of blood-borne viral infections in hemodialysis patients: hepatitis B, hepatitis C, human immunodeficiency virus infections

Aydın

Ergen

Erbakan

et al. 2022

Journal of Health Sciences and Medicine

View full text Add to dashboard Cite

show abstract

“…In particular, hemodialysis patients generally have a high rate of vaccination failure. For example, the rate of vaccination failure for hepatitis B vaccination was 28.3% of hemodialysis patients, but < 10% in the normal population [ 4 ]. Hemodialysis patients also have a higher risk of becoming infected with COVID-19 and, when infected, have a higher associated mortality rate than the normal population [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients

Haase

Lesny²,

Anderson

et al. 2022

J Nephrol

View full text Add to dashboard Cite

Background After the reports of severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine, patients who had received one dose of ChAdOx1-S-nCoV-19 vaccine were recommended a second dose of Pfizer’s BNT162b2 vaccine. In hemodialysis patients, we compared the humoral immunogenicity and tolerability of homologous vaccination with ChAdOx1-nCoV-19/ChAdOx1-nCoV-19 (ChAd/ChAd) and BNT162b2/BNT162b2 (BNT/BNT) with heterologous vaccination of first dose of ChAdOx1-nCoV-19 and a second dose with BNT162b2 (ChAd/BNT). Methods In a multicenter prospective observational study, SARS-CoV-2 spike-IgG antibody levels, Nucleocapsid-protein-IgG-antibodies, and vaccine tolerability were assessed 6 weeks after second SARS-CoV-2 vaccination in 137 hemodialysis patients and 24 immunocompetent medical personnel. Results In COVID-19-naïve hemodialysis patients, significantly higher median SARS-CoV-2-spike IgG levels were found after ChAd/BNT (N = 16) compared to BNT/BNT (N = 100) or ChAd/ChAd (N = 10) (1744 [25th–75th percentile 276–2840] BAU/mL versus 361 [25th–75th percentile 120–936] BAU/mL; p = 0.009; 1744 [25th–75th percentile 276–2840] BAU/mL versus 100 [25th–75th percentile 41–346] BAU/mL; p = 0.017, respectively). Vaccinated, COVID-19-naïve medical personnel had median SARS-CoV-2 spike-IgG levels of 650 (25th–75th percentile 217–1402) BAU/mL and vaccinated hemodialysis patients with prior COVID-19 7047 (25th–75th percentile 685–10,794) BAU/mL (N = 11). In multivariable regression analysis, heterologous vaccination (ChAd/BNT) of COVID-19-naïve hemodialysis patients was independently associated with SARS-CoV-2 spike-IgG levels. The first dose of ChAd and the second dose of BNT after the first vaccination with ChAd (heterologous vaccination, ChAd/BNT) were associated with more frequent but manageable side effects compared with homologous BNT. Conclusions Within the limitations of this study, heterologous vaccination with ChAd/BNT appears to induce stronger humoral immunity and more frequent but manageable side effects than homologous vaccination with BNT/BNT or with ChAd/ChAd in COVID-19-naïve hemodialysis patients. Graphical abstract

show abstract

“…The HBsAg prevalence rates appear to be greater in patients with advanced CKD on treatment in developing (up to 25%) compared with developed countries (up to 10%). Information on the rate of chronic HBsAg carriers among patients with advanced CKD from less developed regions is mostly based on small-sized single-centre surveys [ 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 ].…”

Section: Epidemiology Of Hbv Infection In Advanced Ckd (Dialysis and ...mentioning

confidence: 99%

The Impact of Antiviral Treatment of Hepatitis B Virus after Kidney Transplant and the Latest Insights

et al. 2023

View full text Add to dashboard Cite

Background: The current frequency of hepatitis B virus infection in patients with advanced chronic kidney disease (CKD) (including patients on maintenance dialysis and kidney transplant recipients) is low but not negligible worldwide. HBV has a deleterious effect on survival after a kidney transplant; antiviral treatments improved the short-term outcomes of kidney transplant recipients, but their long-term impact remains uncertain. Aim: The aim of this review is to assess the role of antiviral therapy for HBV in improving survival after a kidney transplant. The recent publication of large surveys has prompted us to update the available evidence on the impact of HBV on patient and graft survival after a kidney transplant. Methods: We have conducted an extensive review of the medical literature, and various research engines have been used. Results: We retrieved several studies (n = 11; n = 121,436 unique patients) and found an association between positive serologic HBsAg status and diminished patient and graft survival after a kidney transplant; the adjusted relative risk (aRR) of all-cause mortality and graft loss was 2.85 (95% CI, 2.36; 3.33, p < 0.0001) and 1.26 (95% CI, 1.02; 1.51, p < 0.0001), respectively. To our knowledge, at least six studies reported improved patient and graft survival after the adoption of antiviral therapies for HBV (this result was reported with both survival curves and multivariable regression). According to novel clinical guidelines, entecavir has been suggested as a ‘first line’ antiviral agent for the treatment of HBV after a kidney transplant. Conclusions: The recent availability of safe and effective antiviral drugs for the treatment of HBV has meant that the survival curves of HBsAg-positive patients on antiviral therapy and HBsAg-negative patients after a kidney transplant can be comparable. Antiviral therapy should be systematically proposed to HBV-positive kidney transplant recipients and candidates to avoid the deleterious hepatic and extra-hepatic effects of chronic HBV replication.

show abstract

Spanish multicentre PIBHE study: Prevalence and immunisation of chronic hepatitis B in haemodialysis patients in Spain

Cited by 7 publications

References 17 publications

Overview of blood-borne viral infections in hemodialysis patients: hepatitis B, hepatitis C, human immunodeficiency virus infections

Overview of blood-borne viral infections in hemodialysis patients: hepatitis B, hepatitis C, human immunodeficiency virus infections

Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients

The Impact of Antiviral Treatment of Hepatitis B Virus after Kidney Transplant and the Latest Insights

Contact Info

Product

Resources

About